| Title |
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance
|
|---|---|
| Published in |
OncoTargets and therapy, January 2014
|
| DOI | 10.2147/ott.s55344 |
| Pubmed ID | |
| Authors |
Leah K O’Shea, Samar Abdulkhalek, Stephanie Allison, Ronald J Neufeld, Myron R Szewczuk |
| Abstract |
Resistance to drug therapy, along with high rates of metastasis, contributes to the low survival rate in patients diagnosed with pancreatic cancer. An alternate treatment for human pancreatic cancer involving targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) was investigated in human pancreatic cancer (PANC1) cells with acquired resistance to cisplatin and gemcitabine. Its efficacy in overcoming the intrinsic resistance of the cell to chemotherapeutics and metastasis was evaluated. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 11% |
| Student > Bachelor | 4 | 11% |
| Student > Ph. D. Student | 4 | 11% |
| Professor | 3 | 8% |
| Student > Master | 3 | 8% |
| Other | 6 | 16% |
| Unknown | 13 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 5 | 14% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Engineering | 3 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Nursing and Health Professions | 2 | 5% |
| Other | 6 | 16% |
| Unknown | 15 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2024.
All research outputs
#6,776,249
of 25,918,104 outputs
Outputs from OncoTargets and therapy
#336
of 3,038 outputs
Outputs of similar age
#72,559
of 324,335 outputs
Outputs of similar age from OncoTargets and therapy
#3
of 23 outputs
Altmetric has tracked 25,918,104 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 3,038 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,335 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.